Minerva Neurosciences Stock Price, News & Analysis (NASDAQ:NERV)

$6.10 0.25 (4.27 %)
(As of 12/14/2017 01:09 AM ET)
Previous Close$5.85
Today's Range$5.90 - $6.25
52-Week Range$4.80 - $14.00
Volume152,915 shs
Average Volume217,723 shs
Market Capitalization$236.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

About Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NERV
CUSIPN/A
Phone+1-617-6007373

Debt

Debt-to-Equity RatioN/A
Current Ratio15.38%
Quick Ratio15.38%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.04 per share
Price / Book2.01

Profitability

Trailing EPS($1.11)
Net Income$-31,040,000.00
Net MarginsN/A
Return on Equity-37.31%
Return on Assets-27.90%

Miscellaneous

Employees11
Outstanding Shares38,700,000

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc (NASDAQ:NERV) announced its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of $0.00 by $0.28. During the same quarter last year, the business earned ($0.24) earnings per share. View Minerva Neurosciences' Earnings History.

Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2017?

3 Wall Street analysts have issued 1-year price targets for Minerva Neurosciences' shares. Their forecasts range from $11.00 to $20.00. On average, they anticipate Minerva Neurosciences' share price to reach $16.00 in the next twelve months. View Analyst Ratings for Minerva Neurosciences.

What are Wall Street analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:

  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/5/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe NERV's two candidates MIN-101 and -202 offer upside to shares. MIN-101, designed to treat negative symptoms in schizophrenia, an unmet need, has demonstrated stat sig benefits in PIIb. MIN-202, partnered with JNJ, may offer an effective tx to insomnia with fewer side effects, and has demonstrated positive data in PIIa with stat sig improvements in key sleep parameters. We assume with Buy and $17 PT." (3/6/2017)

Who are some of Minerva Neurosciences' key competitors?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:

  • Marc D. Beer, Independent Chairman of the Board (Age 50)
  • Richard Russell, President (Age 53)
  • Remy Luthringer Ph.D., Chief Executive Officer, Director (Age 54)
  • Geoffrey Race, Executive Vice President and Chief Financial Officer (Age 54)
  • Joseph Reilly, Chief Operating Officer, Vice President (Age 40)
  • Frederick Ahlholm CPA, Chief Accounting Officer, Vice President (Age 49)
  • Mark Levine, Vice President, General Counsel, Secretary (Age 43)
  • William F. Doyle, Director (Age 54)
  • Hans Peter Hasler, Director (Age 61)
  • David J Kupfer M.D., Independent Director (Age 75)

Who owns Minerva Neurosciences stock?

Minerva Neurosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sphera Funds Management LTD. (1.61%), JPMorgan Chase & Co. (1.00%), Nationwide Fund Advisors (0.29%), Bank of New York Mellon Corp (0.28%), Handelsbanken Fonder AB (0.22%) and Alyeska Investment Group L.P. (0.21%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Institutional Ownership Trends for Minerva Neurosciences.

Who sold Minerva Neurosciences stock? Who is selling Minerva Neurosciences stock?

Minerva Neurosciences' stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., GSA Capital Partners LLP and TD Asset Management Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Mark S Levine and Remy Luthringer. View Insider Buying and Selling for Minerva Neurosciences.

Who bought Minerva Neurosciences stock? Who is buying Minerva Neurosciences stock?

Minerva Neurosciences' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Sphera Funds Management LTD., Nationwide Fund Advisors, Handelsbanken Fonder AB, Bank of New York Mellon Corp, Trexquant Investment LP, Schwab Charles Investment Management Inc. and Sterling Capital Management LLC. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and Marc D Beer. View Insider Buying and Selling for Minerva Neurosciences.

How do I buy Minerva Neurosciences stock?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of Minerva Neurosciences stock can currently be purchased for approximately $6.10.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $236.07 million. The biopharmaceutical company earns $-31,040,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Minerva Neurosciences employs 11 workers across the globe.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 Trapelo Rd Ste 284, WALTHAM, MA 02451-7357, United States. The biopharmaceutical company can be reached via phone at +1-617-6007373 or via email at [email protected]


MarketBeat Community Rating for Minerva Neurosciences (NERV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Minerva Neurosciences (NASDAQ:NERV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$16.00$18.50
Price Target Upside: 164.46% upside164.46% upside164.46% upside85.00% upside

Minerva Neurosciences (NASDAQ:NERV) Consensus Price Target History

Price Target History for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ:NERV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2017CitigroupInitiated CoverageBuy$11.00HighView Rating Details
6/1/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $20.00LowView Rating Details
3/6/2017Jefferies GroupInitiated CoverageBuy -> Buy$17.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Minerva Neurosciences (NASDAQ:NERV) Earnings History and Estimates Chart

Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ NERV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017$0.00($0.28)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.34)($0.27)ViewListenView Earnings Details
5/4/2017Q1 2017($0.30)($0.30)ViewListenView Earnings Details
3/13/2017Q4 2016($0.25)($0.27)ViewN/AView Earnings Details
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.53)($0.27)ViewN/AView Earnings Details
3/26/2015Q414($0.53)($0.40)ViewN/AView Earnings Details
11/6/2014Q3 2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.41)($2.33)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Minerva Neurosciences (NASDAQ:NERV) Earnings Estimates

2017 EPS Consensus Estimate: ($1.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.47)($0.47)($0.47)
Q4 20171($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Minerva Neurosciences (NASDAQ NERV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 73.76%
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ NERV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Marc D BeerDirectorBuy50,000$8.12$406,000.00View SEC Filing  
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.62View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.00View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.00View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.00View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Minerva Neurosciences (NASDAQ NERV) News Headlines

Source:
DateHeadline
BRIEF-Minerva Neurosciences names Richard Russell presidentBRIEF-Minerva Neurosciences names Richard Russell president
www.reuters.com - December 12 at 9:44 AM
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors - GlobeNewswire (press release)Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors - GlobeNewswire (press release)
globenewswire.com - December 11 at 9:59 AM
Minerva Neurosciences, Inc (NERV) Receives Consensus Rating of "Hold" from BrokeragesMinerva Neurosciences, Inc (NERV) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 10 at 1:52 AM
Minerva Neurosciences (NERV) Reports Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202)Minerva Neurosciences (NERV) Reports Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202)
www.streetinsider.com - December 6 at 5:34 PM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia DisorderMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
finance.yahoo.com - December 6 at 9:25 AM
Minerva Neurosciences, Inc (NERV) Given Average Rating of "Hold" by BrokeragesMinerva Neurosciences, Inc (NERV) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 15 at 1:46 AM
FY2017 EPS Estimates for Minerva Neurosciences, Inc Cut by Analyst (NERV)FY2017 EPS Estimates for Minerva Neurosciences, Inc Cut by Analyst (NERV)
www.americanbankingnews.com - November 8 at 12:12 PM
Minerva Neurosciences, Inc (NERV) Releases Quarterly  Earnings ResultsMinerva Neurosciences, Inc (NERV) Releases Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 11:53 AM
BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28
www.reuters.com - November 7 at 7:31 AM
Minerva Neurosciences Inc to Host Earnings CallMinerva Neurosciences Inc to Host Earnings Call
finance.yahoo.com - November 7 at 7:31 AM
Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business UpdatesMinerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
finance.yahoo.com - November 7 at 7:31 AM
Minerva Neurosciences reports 3Q lossMinerva Neurosciences reports 3Q loss
finance.yahoo.com - November 7 at 7:31 AM
Edited Transcript of NERV earnings conference call or presentation 6-Nov-17 1:30pm GMTEdited Transcript of NERV earnings conference call or presentation 6-Nov-17 1:30pm GMT
finance.yahoo.com - November 7 at 7:31 AM
Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy - GlobeNewswire (press release)Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy - GlobeNewswire (press release)
globenewswire.com - November 2 at 6:47 AM
Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product StrategyMinerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy
feeds.benzinga.com - October 31 at 8:50 AM
Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
finance.yahoo.com - October 31 at 6:51 AM
Minerva Neurosciences, Inc (NERV) Set to Announce Quarterly Earnings on WednesdayMinerva Neurosciences, Inc (NERV) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 5:24 AM
Minerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by AnalystsMinerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 21 at 2:42 AM
Minerva Neurosciences, Inc (NERV) Lowered to "Hold" at Zacks Investment ResearchMinerva Neurosciences, Inc (NERV) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 1:06 PM
Teligent, Inc. Announces FDA Approval Of Partnered ANDA For Desonide Lotion, 0.05%Teligent, Inc. Announces FDA Approval Of Partnered ANDA For Desonide Lotion, 0.05%
www.thestreet.com - October 2 at 5:51 PM
 Analysts Expect Minerva Neurosciences, Inc (NERV) to Announce -$0.27 Earnings Per Share Analysts Expect Minerva Neurosciences, Inc (NERV) to Announce -$0.27 Earnings Per Share
www.americanbankingnews.com - September 13 at 4:26 PM
Is Minerva Neurosciences Inc (NERV) Undervalued?Is Minerva Neurosciences Inc (NERV) Undervalued?
finance.yahoo.com - September 13 at 6:59 AM
Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and DevelopmentMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
finance.yahoo.com - September 12 at 5:43 AM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-2Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-2
www.nasdaq.com - September 6 at 6:45 AM
BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexantBRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant
www.reuters.com - September 6 at 6:45 AM
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive DisorderMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
finance.yahoo.com - September 6 at 6:44 AM
Minerva Neurosciences, Inc (NERV) Earns Buy Rating from Analysts at Citigroup IncMinerva Neurosciences, Inc (NERV) Earns Buy Rating from Analysts at Citigroup Inc
www.americanbankingnews.com - September 4 at 5:10 PM
Minerva Neurosciences, Inc (NERV) Given Consensus Recommendation of "Hold" by AnalystsMinerva Neurosciences, Inc (NERV) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 1 at 9:02 AM
Minerva-J&Js Amendment of MIN-202 Contract Wins EU ApprovalMinerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
www.zacks.com - August 29 at 5:16 AM
Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With ... - GlobeNewswire (press release)Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With ... - GlobeNewswire (press release)
globenewswire.com - August 27 at 8:00 PM
Minerva Neurosciences, Inc.: Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With JanssenMinerva Neurosciences, Inc.: Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
www.finanznachrichten.de - August 26 at 7:39 AM
Minerva Neurosciences (NERV) Announces EC Approval of Amendment of MIN-202 Agreement With JanssenMinerva Neurosciences (NERV) Announces EC Approval of Amendment of MIN-202 Agreement With Janssen
www.streetinsider.com - August 26 at 7:39 AM
BRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with JanssenBRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen
www.businessinsider.com - August 26 at 7:39 AM
Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With ... - NasdaqMinerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With ... - Nasdaq
www.nasdaq.com - August 25 at 9:08 AM
Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With JanssenMinerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
finance.yahoo.com - August 25 at 9:08 AM
Minerva Neurosciences, Inc (NASDAQ:NERV) Posts  Earnings Results, Beats Estimates By $0.07 EPSMinerva Neurosciences, Inc (NASDAQ:NERV) Posts Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - August 6 at 12:52 AM
BRIEF-Minerva Neurosciences ‍says phase 2B trial with MIN-117 planned for late 2017BRIEF-Minerva Neurosciences ‍says phase 2B trial with MIN-117 planned for late 2017
www.reuters.com - August 4 at 6:13 AM
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business UpdatesMinerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
finance.yahoo.com - August 4 at 6:13 AM
Minerva Neurosciences reports 2Q lossMinerva Neurosciences reports 2Q loss
finance.yahoo.com - August 4 at 6:13 AM
Edited Transcript of NERV earnings conference call or presentation 3-Aug-17 12:30pm GMTEdited Transcript of NERV earnings conference call or presentation 3-Aug-17 12:30pm GMT
finance.yahoo.com - August 4 at 6:13 AM
American Journal of Psychiatry Publishes Minerva Neurosciences MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in SchizophreniaAmerican Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
finance.yahoo.com - July 31 at 9:59 PM
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest UpdateMinerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update
www.americanbankingnews.com - July 30 at 7:03 AM
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
finance.yahoo.com - July 28 at 6:09 AM
Minerva Neurosciences Announces Departure of DirectorsMinerva Neurosciences Announces Departure of Directors
finance.yahoo.com - July 25 at 6:07 AM
MINERVA NEUROSCIENCES INCMINERVA NEUROSCIENCES INC
www.finanznachrichten.de - July 6 at 3:43 PM
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesMinerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - July 6 at 7:18 AM
Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use inMinerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in
www.nasdaq.com - June 23 at 7:18 PM
Why Minerva Shares Are ClimbingWhy Minerva Shares Are Climbing
247wallst.com - June 1 at 7:38 PM
Minerva Neurosciences, Inc.: Minerva Announces Amended Agreement for MIN-202 in InsomniaMinerva Neurosciences, Inc.: Minerva Announces Amended Agreement for MIN-202 in Insomnia
www.finanznachrichten.de - May 31 at 7:09 PM
A Deep Dive Into Minerva Neurosciences PipelineA Deep Dive Into Minerva Neurosciences' Pipeline
seekingalpha.com - May 16 at 6:31 PM

SEC Filings

Minerva Neurosciences (NASDAQ:NERV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Minerva Neurosciences (NASDAQ:NERV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Minerva Neurosciences (NASDAQ NERV) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.